Search

Displaying results 5391 - 5400 of 10000 in total
  1. Drug

    humanized SMART Anti-IL-12 Antibody

    go.drugbank.com/drugs/DB05848
    Experimental

    IL-12 is a cytokine that may have considerable potential as a target in the therapy of autoimmune diseases. … The humanized anti-IL-12 antibody is an important addition to PDL's already strong pipeline of humanized antibodies being developed for the treatment of autoimmune diseases.

  2. Drug

    Sarracenia Purpurea

    go.drugbank.com/drugs/DB13965
    ApprovedWithdrawn

    However, the use of Sarracenia Purpurea extracts in the clinical setting are limited. … It was used as an injectable pain reliever and during the 19th century, _Sarracenia purpurea_ was used as a treatment of smallpox [A32509].

  3. Drug

    LY-517717

    go.drugbank.com/drugs/DB05713
    Investigational

    LY517717 is an investigational oral direct inhibitor of activated Factor Xa. It is believed to be Lilly's PMD-3112 (licensed from Amgen).

  4. Drug

    ATX-201

    go.drugbank.com/drugs/DB05765
    Investigational

    ATX-201 is one of a family of novel compounds that inhibits microtubule polymerization. It is developed by Kythera Biopharmaceuticals, Inc. for the treatment of actinic keratosis.

  5. Drug

    Talmapimod

    go.drugbank.com/drugs/DB05412
    Investigational

    Talmapimod is the first-generation oral p38 MAP kinase inhibitor developed by Scios. It has shown to be effective to cure inflammatory diseases such as Rheumatoid Arthritis.

  6. Drug

    Piroxicam

    go.drugbank.com/drugs/DB00554
    ApprovedInvestigational

    A cyclooxygenase inhibiting, non-steroidal anti-inflammatory agent (NSAID) that is well established in treating rheumatoid arthritis and osteoarthritis and used for musculoskeletal disorders, dysmenorrhea

    Categories: Antiinflammatory Preparations, Non-Steroids for Topical Use
  7. Drug

    ICX-RHY

    go.drugbank.com/drugs/DB05716
    Experimental

    ICX-RHY is an investigational therapy comprised of cultured allogeneic fibroblasts. … The drug was under investigation in clinical trials in the UK for the treatment of skin erosions in recessive dystrophic epidermolysis bulllosa.

  8. Drug

    IRX-5183

    go.drugbank.com/drugs/DB05653
    Investigational

  9. Drug

    Basic Fibroblast Growth Factor

    go.drugbank.com/drugs/DB14131
    Investigational

    Although it is not approved for use in Canada or the USA, bFGF is currently undergoing investigation in a number of clinical trials. … Basic Fibroblast Growth Factor (bFGF) is a single-chain polypeptide growth factor that plays a significant role in the process of wound healing and is a potent inducer of physiologic angiogenesis.

  10. Drug

    Fluvoxamine

    go.drugbank.com/drugs/DB00176
    ApprovedInvestigational

    It was launched in the US in December 1994 and in Japan in June 1999. As of the end of 1995, more than 10 million patients worldwide have been treated with fluvoxamine. … Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder.